BETAWIN-AHF study: effect of beta-blocker withdrawal during acute decompensation in patients with chronic heart failure

Abstract

In the absence of clear contraindications, BB treatment should be maintained during AHF episodes in patients already receiving BB at home.

Effects on short term outcome of non-invasive ventilation use in the emergency department to treat patients with acute heart failure: A propensity score-based analysis of the EAHFE Registry

“…This is a multicenter, observational, multipurpose, cohort-designed database that includes consecutive patients diagnosed with AHF in 41 Spanish EDs (approximately 7% of EDs of the Spanish Public Health Care System) including both university and community hospitals from all areas of the country. The characteristics of the EAHFE Registry have been published elsewhere [9][10][11]. For the present study, we used Phases 3, 4, and 5 EAHFE Registry patients.…”

The Pathophysiology and New Advancements in the Pharmacologic and Exercise-Based Management of Heart Failure With Reduced Ejection Fraction: A Narrative Review

“…On the contrary, β-blockers are commonly used in the management of heart failure, but their effects can vary depending on whether they are administered for acute or chronic heart failure, with significant implications for acute decompensated heart failure [ 70 , 71 ]. β-blockers, such as carvedilol, metoprolol, and bisoprolol, significantly improve cardiac function when used chronically as they reduce cardiac workload by slowing the heart rate and reducing contractility [ 24 ].…”

“…In cases of acute exacerbation, β-blockers may be temporarily discontinued or adjusted due to exacerbation of symptoms resulting from their negative inotropic effects, which reduce the heart’s ability to pump blood effectively. There is also an additional decompensation risk: the reduction in heart rate and contractility can potentially worsen decompensation during acute episodes, leading to decreased cardiac output and inadequate tissue perfusion [ 23 , 70 , 71 ]. It is crucial for healthcare providers to carefully assess the patient’s condition when considering the use of β-blockers during acute decompensation.…”

Morphine Use in the ED and Outcomes of Patients With Acute Heart Failure

“…The characteristics of the EAHFE Registry have been published elsewhere. [10][11][12] For the present study, we used patients included in the registry in 2011 (2 months of recruitment, 25 participating EDs, n ¼ 3,414) and 2014 (2 months, 27 EDs, n ¼ 3,233). The recruitment dynamics were the same in both periods.…”